Anatara Lifesciences Ltd
ANR.ASXHealth Care
Developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.
Market Data
$0.010
+0.1%$2.8M
-100000.0x
$-0.006
0.00%
-0.2%
Latest Earnings
Appendix 4D & Half Year Report 31 December 2025
25 February 2026
Anatara Lifesciences reported a 56% reduction in net loss to $515k for HY2025, despite a 66% decline in revenue to $178k. The company strengthened its cash position to $1.1M through successful capital raising of $1.2M and achieved positive operating cash flow of $282k, while advancing its promising Anti-Obesity Project with pre-clinical studies showing significant weight management activity. Key points: Net loss reduced by 56% to $515k despite revenue decline, showing improved cost management; Positive operating cash flow of $282k versus $900k outflow in prior period; Cash position strengthened to $1.1M from $101k through successful $1.2M capital raising
Recent Announcements
Appendix 4D & Half Year Report 31 December 2025
Anatara Lifesciences reported a 56% reduction in net loss to $515k for HY2025, despite a 66% decline in revenue to $178k. The company strengthened its cash position to $1.1M through successful capital raising of $1.2M and achieved positive operating cash flow of $282k, while advancing its promising Anti-Obesity Project with pre-clinical studies showing significant weight management activity. Key points: Net loss reduced by 56% to $515k despite revenue decline, showing improved cost management; Positive operating cash flow of $282k versus $900k outflow in prior period; Cash position strengthened to $1.1M from $101k through successful $1.2M capital raising
Get real-time alerts for ANR
Receive AI-powered earnings summaries and instant notifications when Anatara Lifesciences Ltd releases results.
Register Free